SICI-GISE Position paper on the use of the magnesium bioresorbable scaffold Magmaris in clinical practice

G Ital Cardiol

18 Marzo Mar 2020 16 days ago
  • Galli S, Montorsi P

Bioresorbable scaffolds have emerged as a potential breakthrough for the treatment of coronary artery lesions. The need for drug release and plaque scaffolding is temporary, and leaving a permanent stent once the process of plaque recoil and vessel healing has ended might be superfluous or even deleterious exposing the patient to the risk of very late thrombosis, eliminating vessel reactivity, impairing non-invasive imaging and precluding possible future surgical revascularization. This long-term potential limitation of permanent bare metal stents might be overcome by using a resorbable scaffold. The metallic and antithrombotic properties makes the resorbable magnesium scaffold an appealing technology for the treatment of coronary artery lesions. Notwithstanding this, its mechanical properties substantially differ from those of conventional bare metal stents, and previous experience using polymer-based scaffolds has shown that a standardized implantation technique and optimal patient and lesion selection are key factors for a successful implantation. A panel of expert cardiologists gathered to find a consensus on the best practices for Magmaris implantation in a selected patient population and to discuss the rationale for new potential future indications.

Reference

Galli S, Testa L, Montorsi P, Bedogni F, Pisano F, Palloshi A, Mauro C, Contarini M, Varbella F, Esposito G, Caramanno G, Secco GG, D'Amico G, Musumeci G, Tarantini G. SICI-GISE Position paper on the use of the magnesium bioresorbable scaffold Magmaris in clinical practice. G Ital Cardiol 2020 Feb;21(2 Suppl 1):52-59. doi: 10.1714/3311.32822.

Go to PubMed